Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Corso

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
European Journal of Haematology|November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian expertsFrancesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
Haematologica|September 21, 2004
The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myelomaAlessandro Corso, Luciana Barbarano, Patrizia Zappasodi, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 7, 2020
The association between insight and depressive symptoms in schizophrenia: Undirected and Bayesian network analysesMario Amore, Martino Belvederi Murri, Pietro Calcagno, et al.
The New England Journal of Medicine|May 11, 2012
Continuous lenalidomide treatment for newly diagnosed multiple myelomaAntonio Palumbo, Roman Hajek, Michel Delforge, et al.
Annals of Hematology|October 25, 2018
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, et al.
European Journal of Haematology|September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsPaul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
BMC Cancer|November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision frameworkMario Boccadoro, Angelo Belotti, Felice Bombaci, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 22, 2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional StudyMohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, et al.
European Journal of Haematology|January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' RecommendationsAlessandro Corso, Monia Marchetti, Monica Galli, et al.
Hematological Oncology|February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World StudyEnrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
European Journal of Haematology|November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian expertsFrancesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
Haematologica|September 21, 2004
The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myelomaAlessandro Corso, Luciana Barbarano, Patrizia Zappasodi, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 7, 2020
The association between insight and depressive symptoms in schizophrenia: Undirected and Bayesian network analysesMario Amore, Martino Belvederi Murri, Pietro Calcagno, et al.
The New England Journal of Medicine|May 11, 2012
Continuous lenalidomide treatment for newly diagnosed multiple myelomaAntonio Palumbo, Roman Hajek, Michel Delforge, et al.
Annals of Hematology|October 25, 2018
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, et al.
European Journal of Haematology|September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsPaul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
BMC Cancer|November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision frameworkMario Boccadoro, Angelo Belotti, Felice Bombaci, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 22, 2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional StudyMohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, et al.
European Journal of Haematology|January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' RecommendationsAlessandro Corso, Monia Marchetti, Monica Galli, et al.
Hematological Oncology|February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World StudyEnrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Pageof 6